About Professor Thomas Borody

Professor Borody is most famous for his ground-breaking work developing the triple therapy cure for peptic ulcers in 1987, which has saved hundreds of thousands of lives, and the Australian health system more than $10 billion in medical care and operations.

Professor Borody founded the Centre for Digestive Diseases (CDD) in 1984 after a distinguished career with leading hospitals including St Vincent’s in Sydney and the Mayo Clinic in the USA.

He is a world-renowned leader in the clinical microbiota dating back to 1988 when he started performing what is now called Fecal Microbiota Transplantation (FMT).

Professor Borody holds over 150 patents in areas such as; treatment of Helicobacter pylori, Crohn’s disease, bowel lavage, IBS and FMT.

Fecal Microbiota Transplantation (FMT)

As a practicing clinician leading the CDD in Australia, he has overseen over 12,000 FMTs, creating a wealth of proprietary clinical data and insights.

Inflammatory disease and infection

In addition, Dr. Borody has established novel therapies in the gastrointestinal field, including areas such as inflammatory bowel disease, irritable bowel syndrome, CDI, parasite infestation, and resistant Helicobacter pylori via a bismuth-based ‘Triple Therapy’.

Peer review

His knowledge and expertise are sought after by clinicians from around the world. He is  a reviewer for leading medical journals including:

  • Journal of Clinical Gastroenterology
  • World Journal of Gastrointestinal Pharmacology and Therapeutics (Editorial Board)
  • American Journal of Gastroenterology
  • Digestive Diseases and Sciences Endoscopy
  • Journal of Gastroenterology and Hepatology
  • Medical Journal of Australia
  • Digestive and Liver Diseases

Biopharma founder

He is also a scientific founder and scientific advisor to a number of biopharma companies company.

  1. PUBLICATIONS

     

    1. Borody TJ, Leis S, Gadalla S, Dawson V, Jaworski A. Treatment of First-time Clostridium difficileInfection with Fecal Microbiota Transplantation. Am J Gastroenterol 2015;110: S-1354
    2. Aitken J, Borody TJ, et al. Demonstration of Intracellular Mycobacterium Species In Crohn’sDisease Using Novel Technologies. Am J Gastroenterol 2015;110: S-1990
    3. Borody TJ, Grippi D, Le Busque A, Jaworski A, Dawson V, Gadalla S. Comparison ofEradication Protocols For Dientamoeba fragilis. Am J Gastroenterol 2015;110: S-1359
    4. Borody TJ, Grippi D, Le Busque A, Gadalla S, Jaworski A. Improved Eradication Protocol ForBlastocystis hominis. Am J Gastroenterol 2015;110: S-1363
    5. Paramsothy S, TJ Borody et al. Gastroenterologist Perceptions of Faecal MicrobiotaTransplantation. World J Gastroenterol 2015; 21 (38): 10907
    6. Borody TJ; Connelly N; Mitchell SW. Fecal Microbiota Transplantation in Gastrointestinal Diseases – What Practicing Physicians Should Know.
      Polish Archives of Internal Medicine 2015; 125:852
    7. 2015-Agrawal G, Borody TJ et al-Combining Infliximab, Anti-MAP and Hyperbaric Oxygen Therapy for Resistant Fistulizing Crohn’s Disease. Future Science OA 2015; 1:FS077
    1. Lin E, Borody TJ, et al. Twelve Week Storage Trial of Microbial Viability In Lyophilized And Frozen Fecal Microbiota Preparations. Gastroenterol 2015; 148: S-962
    2. Borody TJ; Peattie D; Mitchell S. Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond. Antibiotics 2015; 4: 254-266
    3. Leis S; TJ Borody et al. Fecal microbiota transplantation: A ‘How-To’ guide for nurses. Collegian 2015; 22: 445
    4. TJ Borody; Leis S et al. Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. UpToDate, Feb 2015
    5. Borody TJ; Finlayson S. Fecal microbiota transplantation for Clostridium difficile infection: a surgeon’s perspective. Seminars in Colon and Rectal Surgery 2014; 25: 163-166
    6. Borody TJ; Finlayson S; Paramsothy S. Is Crohn’s disease ready for fecal microbiota transplantation? J Clin Gastroenterol 2014; 48: 582-583
    7. Kelly C; Ihunnah C, Borody TJ et al. Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients. Am J Gastroenterol 2014; 109:1065-1071
    8. Agrawal M; Aroniadis OC; Brandt LJ; Borody TJ et al. A long-term follow-up study of the efficacy and safety of fecal microbiota transplant (FMT) for recurrent/severe/complicated C. difficile infection (CDI) in the elderly. Gastroenterol 2014; 146: S42-43 (A152)
    9. Agrawal G, Borody TJ, Chamberlin W. ‘Global warming’ to Mycobacterium avium subspecies paratuberculosis. Future Microbiol 2014; 9 (7): 829-832
    10. Borody TJ; Peattie D; Kapur A. Could fecal microbiota transplantation cure all Clostridium difficile infections? Future Microbiol 2014; 9:1-3
    11. Borody TJ; Brandt LJ; Paramsothy S. Therapeutic faecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol 2014; 30:97-105
    12. Smits LP; Bouter KE; de Vos W, Borody TJ et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterol 2013; 145:946-53
    13. Ihunnah C; Khoruts A; Fischer M et al. Fecal microbiota transplantation (FMT) for treatment of Clostridium difficile infection (CDI) in immunocompromised patients. Am J Gastroenterol 2013; 108(Suppl 1):S179-80. 2013 ACG Governors Award for Excellence in Clinical Research
    14. Borody TJ; Finlayson S; Nowak A et al. Anti-MAP therapy for pediatric Crohn’s disease. Am J Gastroenterol 2013; 108 (Suppl 1): S516.
    15. Brandt L, Aroniadis O, Greenberg A et al. Safety of fecal microbiota transplantation (FMT) in immunocompromised (IC) patients with inflammatory bowel disease (IBD). Am J Gastroenterol 2013; 108 (Suppl 1): S556. 2013 ACG Presidential Poster Award
    1. Borody TJ; Wettstein A; Nowak A et al. Fecal microbiota transplantation (FMT) eradicates Clostridium difficile infection (CDI) in inflammatory bowel disease (IBD). 21st United European Gastroenterology Week 2013, Session Beneficial and detrimental effects of bacteria in the GI tract, October 15 2013.
    2. Aroniadis OC; Brandt LJ; Greenberg et al. Long-Term Follow-up Study of Fecal Microbiota Transplantation (FMT) for Severe or Complicated Clostridium difficile Infection (CDI). Gastroenterol 2013; 144 (Suppl 1): S185
    3. Borody TJ; Paramsothy S; Agrawal G. Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep 2013;15:337-44
    4. Borody TJ; Wettstein AR; Benstock S et al. Superior diagnosis of H.pylori infection by 14C-urea HeliCapTM capsules versus standard PyTest® capsules. Gastroenterol 2013; 144 (Suppl 1): S214
    5. Borody TJ,;Brandt LJ; Paramsothy S et al. Fecal microbiota transplantation: a new standard treatment option for Clostridium difficile. Expert Rev Anti Infect Ther 2013; 11: 447-449
    6. Borody TJ; Nowak A; Finlayson S. The GI Microbiome and its Role in Chronic Fatigue Syndrome: a Summary of Bacteriotherapy. ACNEM Journal 2013; 31:3-8
    7. Borody TJ; Campbell J. Fecal Microbiota Transplantation Techniques, Applications, Issues. Gastroenterol Clin North Am 2012; 41:781-803
    8. Borody TJ; Wettstein AR; Finlayson S et al. Diagnostic value of Fundic Red Spots in Helicobacter pylori. Am J Gastro 2012; 107(S1):A139
    9. Borody TJ, Nowak A, Torres M et al. Bacteriotherapy in Chronic Fatigue Syndrome (CFS): A retrospective review. Am J Gastro 2012; 107(S1):A1481
    10. Borody TJ; Agrawal G; Campbell J et al. Rescue H. pylori therapy in the clinical setting. Am J Gastro 2012; 107(S1):A1486
    11. Borody TJ; Wettstein A; Campbell J et al. Fecal Microbiota Transplantation in Ulcerative Colitis: review of 24 years experience. Am J Gastro 2012; 107(Supp 1):A1644
    12. Borody TJ; Wettstein, A; Leis, S et al. Resistant fistulising Crohn’s Disease treated with combination of infliximab, Anti-Map and Hyperbaric Oxygen (HBO). Am J Gastro 2012; 107 (Supp 1):A1655
    13. Borody TJ; Wettstein AR; Benstock S et al. Single transcolonoscopic infusion of three anti- protozoal agents for difficult Blastocystis hominis infections. Gut 2012; 61(Suppl 3):A292
    14. Gitlin L; Borody TJ; Chamberlin W et al. Mycobacterium avium ss paratuberculosis-associated diseases: piecing the Crohn’s puzzle together. J Clin Gastroenterol 2012; 46(8): 649–55
    15. Campbell J; BorodyTJ; Leis S. The many faces of Crohn’s Disease: Latest concepts in etiology, OJIM 2012; 2(2):107-115
    1. Borody TJ; Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2011; 9(2):88-96
    2. BAKKEN,JS; BORODY TJ; BRANDT,LJ et al. Fecal microbiota transplantation Workgroup, Treating Clostridium difficile infection with fecal microbiota transplantation, Clin Gastroenterol and Hep 2011; 9:1044–1049
    3. Borody,TJ; Torres, M; Campbell, JL et al. Reversal of inflammatory Bowel disease (IBD) with recurrent Faecal Microbiota Transplants (FMT), AM J Gastro 2011; 106(S2):A979
    4. Borody TJ; Campbell JL; Torres M et al. Reversal of Idiopathic Thrombocytopenic Purpura (ITP) with fecal microbiota transplantation (FMT), AM J Gastro 2011; 106(S2):A941
    5. Chamberlin W; Borody TJ; Campbell J Primary treatment of Crohn’s disease combined antibiotics taking centre stage, Expert Rev. Clin. Immunol. 2011; 7(6), 751–760
    6. Borody TJ; Wettstein A; Campbell,J et al. Intra-colonic infusion of anti-parasite agents for resistant Blastocystis hominis Long term follow up, AM J Gastro 2011; 106(S2):A421
    7. Borody TJ; Leis SM; JL Campbell, et al. Fecal microbiota transplantation (FMT) in Multiple Sclerosis (MS), AM J Gastro 2011; 106(S2):A942
    8. Brandt LJ; Borody TJ and Campbell J. Endoscopic Fecal Microbiota Transplantation 2, J Clin Gastroenterol 2011; 45(8): 655-657
    9. Borody TJ; Rosen DM; Torres M et al. Myoclonus-dystonia affected by GI Microbiota, AM J Gastro 2011; 106(S2):A940
    10. Borody TJ; Campbell J. Fecal microbiota transplantation: current status and future directions. Expert Rev. Gastroenterol. Hepatol. 2011; 5(6): 653–655
    11. Bakken JS; Borody TJ; Brandt LJ et al. (Fecal microbiota transplantation Workgroup), Treating Clostridium difficile infection with fecal microbiota transplantation, Clin Gastroenterol and Hep 2011; 9(12):1044-9
    12. Brandt LJ; Borody TJ, Campbell J. Endoscopic Fecal Microbiota Transplantation ‘‘First-Line’’ Treatment for Severe Clostridium difficile Infection? J Clin Gastroenterol 2011; 45(8): 655-657
    13. Chamberlin W; Borody TJ and Campbell J 2011, Primary treatment of Crohn’s disease combined antibiotics taking centre stage. Expert Rev. Clin. Immunol. 2011; 7(6): 751–760
    14. Grehan MJ; Borody TJ; Leis SM et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora, J Clin Gastroenterol, 2010; 44:551-561
    15. Wettstein A; Borody TJ; Wee T et al. Novel intra-colonic infusion of three anti-parasite agents for resistant Blastocystis hominis infections, Gut, 2009; 58(Suppl II):A113
    16. Borody TJ; Campbell J; Torres M et al. Changes in Crohn’s Disease activity index and C- reactive protein levels during anti-MAP therapy AM J Gastro 2009; 104(S3):A1293
    17. Borody TJ; Campbell J; Torres M et al. Entamoeba Histolytica: Another cause of Crohn’s Disease, AM J Gastro 2009; 104(S3):A990
    18. Borody TJ; Torres M; Campbell J et al. Treatment of severe constipation improves Parkinson’s Disease (PD) symptoms, AM J Gastro 2009; 104(S3):A999
    19. Borody TJ. Is the Infected Patient too ‘Difficile’ to Treat? The Australian Society for Microbiology. Perth 2009 SY03.1
    1. Borody TJ; Ketheeswaran S; Leis S. Anti-MAP Rescues anti-TNF Failures for over 4 years, Gastroenterol 2009; 136(5) Suppl 1:A-681
    2. Borody TJ; Torres M; Hills L. Colchicine plus Olsalazine for Treatment of Constipation- Predominant Irritable Bowel Syndrome, Gastroenterol 2009; 136(5) Suppl 1:A-484
    3. Borody TJ; Leis S; Torres M. Years continuous Anti-MAP Therapy for Crohn’s – Observation of Side Effects, AM J Gastro 2008; 103(S1):A1163
    4. Borody TJ; Foell D; Wittkowski H et al. Phagocyte-Specific SI00 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease, J Pathol. 2008; 216:183-192.
    5. Borody TJ ; Wettstein AR; Leis S et al. Clostridium difficile complicating Inflammatory Bowel Disease: Pre- and post-treatment findings, Gastroenterol 2008; 104(4) Suppl 1:A-361
    6. Borody TJ; Wettstein AR; Campbell J et al. Rapid and superior diagnosis of H. Pylori infection by 14C-urea HeliprobeTM test versus the PYtest® Gastroenterol 2008; 104(4) Suppl 1:A-329
    7. Ramrakha S; Borody TJ; Herdman KJ et al. Nasal vs. oronasal oxygenation and capnography during endoscopy, Gastrointestinal Endoscopy; 2008;67(5):AB283
    8. Foell D; Ren Z; Wittkowski H; Daebritz J; Roth,J; Borody TJ and Clancy R. Mucosal release of phagocyte-specific S100 proteins is strongly enhanced during active inflammatory bowel disease, J Pathol. 2008; 216(2):183-92
    9. Ren Z; Turton, J; Borody TJ et al. Selective Th2 pattern of cytokine secretion in Mycobacterium avium subsp. Paratuberculosis infected Crohn’s disease, J Gastroenterol Hepatol 2008; 23(2):310-4
    10. Borody TJ; Wettstein AR; Leis S; Torres M. Use of Combination therapy as first line and salvage therapy in parasite infection, Gut, 2007; 56 (suppl III):A303
    11. Chamberlain W; Borody TJ; Naser S. MAP-associated Crohn’s Disease, MAP, Koch’s postulates, causality and Crohn’s Disease. Digestive and Liver Disease 2007; 39:790-794
    12. Borody TJ. Bilkey S. Wettstein AR. Leis S. Pang G. Tye S. Anti-mycobacterial therapy in Crohn’s disease heals mucosa with longitudinal scars. [Clinical Trial. Journal Article] Digestive & Liver Disease 2007; 39(5):438-44
    13. Borody TJ; Heifets LB. Severe recurrent Crohn’s Disease of ileocolonic anastomosis and antimicrobial (anti-mycobacterial therapy) Gut 2006; 55:1211
    14. Borody TJ; PSK. A Protein-Bound Polysaccharide from Coriolus Versicolor, In Combination With Standard Treatments Extends Overall Survival and Disease-Free Survival In Cancer Patients. 2006 Royal Australasian College of Physicians. Internal Medicine Journal 2006; 36 (Suppl. 4): A141-A162
    15. Ramrakha SR; Borody TJ; Wettstein, A et al. Investigating the tolerability of four bowel preparations – the taste test, J Gastroenterol Hepatol, 2006; 21 (Suppl;4): A286-A299
    16. Borody TJ; Bilkey S; Wettstein AR et al. Anti-Mycobacterium avium SS Paratuberculosis (MAP) Therapy and fistula closure in patients with Severe Crohn’s Disease, Am J Gast, 2006; A101:S440
    17. Borody TJ; Pang G; Wettstein AR et al. Efficacy and safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection, Aliment Pharmacol Ther, 2006; 23:481-488
    18. Borody TJ; Clancy R; Pang G Australian Anti-map trials, Microbial-host interactions workshop. 2006
    1. Borody TJ; Ramrakha S; Pang G et al. Effects of supplemental oxygen during endoscopy, J Gastroenterol Hepatol, 2005; 20(Suppl): A49
    2. Borody TJ; Ren Z; Pang G et al. Selective reduction of anti-Helicobacter pylori IgG subclass antibody in gastric carcinoma, J Gastroenterol Hepatol, 2005; 20:1338-1343
    3. Borody TJ; Henriksson A; Clancy R Probiotics under the regulatory microscope, Expert Opin. Drug Saf, 2005; 4(6): 1135-1143
    4. Borody TJ; Clancy R; Wettstein AR et al. Anti-MAP therapy in the treatment of active Crohn’s disease, J Gastroenterol Hepatol, 2005; 20(suppl)A2
    5. Borody TJ; Clancy R; Wettstein A et al. Anti-MAP therapy induces and maintains remission in severe Crohn’s disease, Ann NY Acad Sci, 2005 Münster Germany, 2-3
    6. Borody TJ; Ren Z; Pang G et al. Evaluation of anti-Helicobacter pylori IgG2 antibody for the diagnosis of Helicobacter pylori infection in western and Chinese populations. Aliment Pharmacol Ther, 2005; 21: 83-89
    7. Borody TJ. How effective are quadruple therapies as first-line H. pylori eradication therapies? Nature Clinical Practice – Gastroenterol Hepatol, 2005; 2:174-175 (Practice Point)
    8. Borody TJ; Leis SM; Chongman J et al. Novel appearance of healing mucosa following antimycobacterium avium paratuberculosis for Crohn’s disease, J Gastroenterol Hepatol, 2004; 19(Suppl):A210
    9. Borody TJ; Herdman KJ; Wettstein A et al. Use of hyperlac in Coeliac disease and its effect on disaccharidase deficiency, J Gastroenterol Hepatol, 2004; 19(Suppl):A222 (abstract)
    10. Borody TJ; Wettstein AR; Herdman KJ et al. Dientamoeba fragilis (Df) and Irritable Bowel Syndrome (IBS), 2004 ASM Sydney National Conference p17
    11. Borody TJ; Warren EF; Leis SM et al. Bacteriotherpay using fecal flora: toying with human motions, J Clin Gastroenterol, 2004; 38(6):475-83
    12. Clancy R; Borody TJ; Ren Z; Pang G. Can the response to eradication therapy in helicobacter pylori infection be predicted? Can J Gastroenterol, 2004; 17(Suppl.B):58B-61B (abstract)
    13. Meta-analysis: the efficacy, adverse events and adherence related to first line anti-Helicobacter pylori quadruple therapies. Commentary to Aliment Pharmacol Ther, 2004; 20: 1071-1082
    14. O’Morain C; Borody TJ; Farley A et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study, Aliment Pharmacol Ther, 2003; 17(3): 415- 20
    15. Borody TJ; Ashman O Lactoferrin: milking ulcers? Digest Liver Dis, 2003; 35: 691-3
    16. Borody TJ; Leis SM; Chongnan J et al. Faecal bacteriotherapy (FB) for chronic C. difficilesyndromes, J Gastroenterol Hepatol, 2003; 18: B8 (Abstract)
    17. Borody TJ; Warren EF; Leis S et al. Treatment of ulcerative colitis using fecal bacteriotherapy,J Clin Gastroenterol, 2003; 37(1): 42-7
    18. Borody TJ; Ren Z; Pang G; Clancy R Impaired host immunity contributes to Helicobacter pylorieradication failure, Am J Gastroenterol, 2002; 97(12):3032-7
    19. Borody TJ; Robertson C; Wettstein A et al. Irritable bowel syndrome and Dientamoeba fragilis,IBIS News and Views, 2002; 4-5
    20. Borody TJ; Clancy R; Warren EF et al. Varying gastric sensitivities of H. Pylori, J Gastroenterol Hepatol, 2002; 17(Suppl):A102
    1. Borody TJ; Warren,EF; Wettstein A et al. Eradication of Dientamoeba fragilis can resolve IBS- like symptoms J Gastroenterol Hepatol, 2002; 17(Suppl):A103
    2. Borody TJ; Warren EF; Recabarren, P et al. Rifabutin – key to H. pylori rescue therapy? J Gastroenterology Hepatol, 2002; 17(Suppl):A102
    3. Borody TJ; Leis S; Warren EF; Surace R, Treatment of severe Crohn’s disease using antimycobacterial triple therapy – approaching a cure? Digest Liver Dis, 2002; 34(1): 29-38
    4. Baladas HG; Borody TJ; Smith GS et al. Laparoscopic excision of a Brunner’s gland hamartoma of the duodenum, Surg Endoscopy, 2002; 16: 1636
    5. Sintchenko V; Veroerd,P; Mitchell H; Sacco J; Borody TJ Direct antibiotic susceptibility testing of Helicobacter pylori: does it have a role? J Gastroenterol Hepatol, 2001; 16: A35 (abstract).
    6. Borody TJ; Leis S; McGrath K et al. Treatment of chronic constipation and colitis using human probiotic infusions, In: Proceedings of Prebiotics and Probiotics and the New Foods Conference, Rome, 2001; 2-4: 228 Abstract
    7. Borody TJ. Letter to the Editor – Response to Drs Famularo et al. AJG 2001;96 (7) 2262 – 2264
    8. Wettstein A; Borody TJ; Warren E. Skewered diverticulum: another cause of abdominal pain,Internal Med J, 2001; 31(8): 495-6
    9. Ren Z; Pang G; Clancy R; Li LC; Soon-Lee C; Batey R; Borody TJ; Dunkley M. Shift of thegastric T-Cell response in gastric carcinoma, J Gastroenterol Hepatol, 2001; 16(2): 142 – 148
    10. Borody TJ. Response to “Fecal bacteriotherapy or probiotics for the treatment of intestinaldiseases?” Am J Gastroenterol, 2001; 96: 2262-3
    11. Mitchell HM; Brusentsev S; Hazell SL; Borody TJ et al. A high level of primary resistance to metronidazole and clarithromycin in previously untreated symptomatic patients presenting for endoscopy in Australia, Gut, 2000; 47:A107
    12. Borody TJ. Flora power – fecal bacteria cure chronic C. difficile diarrhoea (editorial). Am J Gastroenterol, 2000; 95(11):3028-3029
    13. Borody TJ; Leis S; Surace R et al. Treatment of severe Crohn’s disease using rifabutin- macrolide-clofazimine combination – results at 38-43 months, J Gastroenterol Hepatol, 2000; 15:J102
    14. Borody TJ; Leis S; Surace R; Goodger J. Treatment of severe Crohn’s disease (CD) using rifabutin-macrolide-clofazimine combination: results at 30-37 months, Gastroenterology, 2000; 118:A1334 Abstract
    15. Borody TJ. Helicobacter pylori pandemic – The Evolving Concepts 2000
    16. De Boer WA; Borody TJ. Treatment failures and secondary resistance to antibiotics. A growingconcern in Helicobacter pylori therapy, Digest Liver Dis, 2000; 32:673-5
    17. Ren Z; Pang G; Lee R; Batey R; Dunkley M; Borody TJ; Clancy R. Circulating T-cell response toH. pylori infection in chronic gastritis, Helicobacter, 2000; 5(3):135-41
    18. Lignell A; Surace R; Bottiger P; Borody TJ. Symptom improvement in Helicobacter pylori-positive non-ulcer dyspeptic patients after treatment with the carotenoid Astaxanthin, Abstract, 12th International Carotenoid Symposium, Cairns, Australia 1999
    19. Borody TJ; Carsula S; O’Shea J et al. Macroscopic colitis – a separate entity? J Gastroenterol Hepatol, 1999; 14:A172
    1. Borody, TJ. Helicobacter pylori eradication failure – “Salvage” therapies needed. Ital J. Gastroenterol Hepatol, 1998; 30(4):375-7 Commentary
    2. Borody,TJ; Pearce,L; Bampton PA et al. Modified Clarithromycin – Quad Therapy as “Salvage” treatment for H. pylori eradication failure (EF), J Gastroenterol Hepatol, 1998; 13(Suppl):A174
    3. Borody TJ; Pearce L; Bampton PA et al. In vitro Helicobacter pylori resistance to metronidazole and clarithromycin in an Australian population, J Gastroenterol Hepatol, 1998; 13(Suppl):A157
    4. Borody TJ; Shortis NP; Reyes E. Eradication Therapies for Helicobacter pylori, J Gastroenterol, 1998; 33(Suppl)10:53-56
    5. Borody TJ; Pearce L; Bampton PA et al. Eradication of H. pylori using pantoprazole quad therapy in routine consultants practice, J Gastroenterol Hepatol, 1998; 13(Suppl):A140
    6. Talley NJ; Chang FY; Wyatt,JM; Adams S; Lau A; Borody TJ et al. Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection, Aliment Pharmacol Ther, 1998; 12:527-32.
    7. Borody TJ; Pearce L; Bampton PA; Leis S. Treatment of severe Crohn’s disease (CD) using rifabutin-macrolide-clofazimine combination: interim report, Gastroenterol, 1998; 114(Suppl):A938
    8. De Boer WA; Borody TJ. Towards monotherapy for Helicobacter pylori infection: first result with a single triple capsule, Gastroenterol 1998, 114(Suppl):A98
    9. Bampton PA; Shortis N; Pearce L; Borody TJ. A cost analysis of different “test and treat” strategies for the management of patients on maintenance therapy for peptic ulcer disease, J Gastroenterol Hepatol, 1997; 12(Suppl):A246
    10. Pearce L; Bampton P; Borody TJ; Shortis NP. Modification of the colonic microflora using probiotics – The way forward? Gut, 1997; 41: A63
    11. Borody TJ. A man with dyspepsia, Patient Management, 1997; 26: 83
    12. Pearce LM; Shortis NP; Leis SM; Borody TJ. The use of probiotic therapy as a novel approach to the management of irritable bowel syndrome: a preliminary study, J Gastroenterol Hepatol, 1997; 12(Suppl): A129
    13. Borody TJ; Bampton P; Moont M et al. Letter Re: W de Boer: Gastric outlet obstruction and Helicobacter pylori, Am J Gastroenterol, 1997; 92(9):1576-7
    14. Borody TJ. Gastro-oesophageal reflux disease, Clinical Concepts, 1997; 2-4
    15. Borody TJ. What is the optimal therapy for Helicobacter pylori eradication? IN: OESO – TheEsophagogastric Junction. John Libbey (ed), Eurotext. Paris, 1996; 653-6 Abstract
    16. Borody TJ; Pearce L; Shortis NP et al. Occult H. pylori infection: detection and treatment,Gastroenterol, 1996; 110(Suppl): A68
    17. Borody TJ; Shortis NP; Chongnan J et al. Eradication failure (EF) after H. pylori treatment –further therapies, Gastroenterol, 1996; 110(Suppl): A67
    18. Borody TJ; Andrews P; Shortis NP et al. Eradicating H. pylori – are we winning the battle? In: Proceedings of Helicobacter pylori and Gastric Cancer: State of the Art, 1996 Ulm Germany 23-24
    19. De Boer WA; Thys JC; Borody TJ et al. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens, Eur J Gastroenterol Hepatol, 1996; 8(7):641-3
    1. Borody TJ. What is the optimal therapy for Helicobacter pylori eradication? Russ Gastroenterol Journal, 1996; 3: 42-6. (article in Russian)
    2. Borody TJ; Pearce L; Shortis N; Chongnan J. From Intestinal Metaplasia to Gastric Cancer – Whither surveillance? Helicobacter pylori and Gastric Cancer – State of the Art Congress, 1996; Ulm Germany, 23-24
    3. Borody TJ; Andrews P; Shortis N. Evaluation of Whole Blood Antibody Kit to Detect Active Helicobacter pylori Infection. Am J Gastroenterol, 1996; 91(12):2509-12
    4. Borody TJ. Bacteriotherapy for Chronic Fatigue Syndrome – A long term follow-up study, Proceedings of ACMA Complementary Medicine Sydney 1995
    5. Borody TJ; Andrews P; Fracchia G et al. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori, Gut, 1995; 37(4):477-81
    6. Borody TJ. Dyspepsia, Current Therapeutics, 1995; 24-5
    7. Andrews P; Borody TJ; Shortis N; Thompson S. Bacteriotherapy for Chronic Constipation – Along term follow-up . Gastroenterol, 1995; 108:A563 Abstract
    8. Borody TJ; Andrews P; Shortis NP; Hyland L. 7 Day Therapy for Helicobacter pylori.Gastroenterol, 1995; 108:A62 Abstract
    9. Borody, TJ; Clark IW; Andrews P et al. Eradication of Helicobacter pylori may not reversesevere gastric dysplasia, Am J Gastroenterol, 1995; 90(3): 498-9
    10. Borody TJ. Methods of Oxygen Delivery during Upper Gastrointestinal Endoscopy, Endoscopy,1995; 26(3): 320-1
    11. Borody TJ. Helicobacter infection – The current state of play, Current Therapeutics 1994; 1:9-12
    12. Borody TJ; Andrews P; Mancuso N et al. Helicobacter pylori reinfection rate, in patients with cured duodenal ulcer, Am J Gastroenterol, 1994; 89(4):529-32
    13. Borody TJ; Andrews P; Shortis NP et al. Non-ulcer Dyspepsia sub-groups and therapy for Helicobacter pylori, Am J Gastroenterol, 1994; 89:1365
    14. Borody TJ; Andrews P; Shortis NP. Features of patients who fail all attempts at Helicobacter pylori (HP) eradication, Am J Gastroenterol, 1994; 89:1365
    15. Borody TJ; Andrews P Shortis NP et al. Failure to use combined tests may miss Helicobacter pylori (HP) diagnosis. Am J Gastroenterol, 1994; 89(8):1348
    16. Andrews P; Borody TJ; Shortis NP et al. Chronic Constipation (CC) may be reversed by “Bacteriotherapy”, Gastroenterol, 1994; 106:A459
    17. Borody TJ; Andrews P; Shortis NP et al. Intestinal Metaplasia (IM) – Occurrence in Korean vs Matched Australian Patients with H. pylori Gastritis, Gastroenterol, 1994; 106:A56
    18. Borody TJ; Andrews P; Shortis NP et al. Optimal H. pylori (HP) Therapy – A Combination of Omeprazole and Triple Therapy (TT), Gastroenterol, 1994; 106:A55
    19. Borody TJ; Andrews P; Shortis NP et al. Eradication of H. pylori in Dyspeptic Patients with Prior DU Surgery, Gastroenterol, 1994; 106:A55
    20. Borody TJ; Brandl S; Andrews P et al. Use of High Efficacy, Lower Dose Triple Therapy to Reduce Side Effects of Eradicating Helicobacter pylori, Am J Gastroenterol, 1994; 89(1):33-8
    21. Andrews P; Borody TJ; “Putting back the bugs”: bacterial treatment relieves chronic constipation and symptoms of Irritable Bowel Syndrome, Med J Aust, 1993; 159:633-4
    1. Borody TJ; Andrews P; Jankiewicz E et al. Apparent reversal of early gastric mucosal atrophy after Triple Therapy for Helicobacter pylori. Am J Gastroenterol, 1993; 88(8):1266-68
    2. Brandl S; Borody TJ; Andrews P et al. Supplemental oxygen therapy during endoscopy and recovery (Letter), Gastrointestinal Endoscopy, 1993; 39: 209
    3. Borody TJ; Andrews P; Brandl S; Carroll M; H. pylori (HP) eradication side effects, compliance : 14 day vs 12 day Triple therapy (TT). Gastroenterology, 1993; 104:A44
    4. Borody, TJ; Andrews P; Brandl S et al. Does H. pylori (HP) play a role in esophageal reflux? Gastroenterol, 1993; 104:A44
    5. Borody TJ; Andrews P; Brandl S; Devine M. Relevance of in-vitro metronidazole resistance to H. pylori (HP) eradication and eradication failure, Gastroenterol 1993; 104:A44
    6. Borody TJ. Laparoscopic vagotomy for chronic duodenal ulcer (Letter to the Editor), Med J Aust, 1992; 156(2):140
    7. Borody TJ; Andrews P; Mancuso N et al. E Helicobacter pylori reinfection 4 years post- eradication, Lancet, 1992; 339(8804):1295
    8. Mancuso N; Borody TJ; Ostapowicz N et al. Frequent early extracorporeal shock wave lithotripsy and simvastatin accelerate gallbladder fragment clearance, Gastroenterol, 1992; 102:A321
    9. Borody TJ; Brandl S; Andrews P et al. High Efficacy, Low dose triple therapy (TT) for Helicobacter pylori (HP) Gastroenterol, 1992; 102(4):A44
    10. Borody TJ; Brandl S; Andrews P et al. H. pylori eradication Failure (EF) – Further treatment possibilities. Gastroenterol, 1992; 102:A43
    11. Andrews PJ; Barnes P; Borody TJ. Chronic constipation reversed by restoration of bowel flora. A case and hypothesis, Eur J Gastroenterol Hepatol, 1992; 4:245-7.
    12. Borody TJ; Brandl S; Andrews P et al. Helicobacter pylori-negative gastric ulcer. Am J Gastroenterol, 1992; 87(10):1403-6
    13. Borody, TJ; George, LL; Brandl, S et al. Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication, Am J Gastroenterol, 1992; 87(10):1390
    14. Axon ATR; Borody TJ; Dixon M et al. Panel Discussion: Short-term and long-term consequences of gastritis and duodenitis. Eur J Gastroenterol Hepatol, 1992; 4(Suppl 2):S53-S64
    15. Borody TJ. Possibilities for Helicobacter pylori suppression/eradication, Eur J Gastroenterology, 1992; 4(Suppl 2):S37-S40
    16. Borody TJ; George LL; Brandl S et al. Helicobacter pylori eradication with doxycycline: metronidazole: bismuth subcitrate triple therapy, Scand J Gastroenterol, 1992; 27(4): 281-4
    17. Brandl S; Borody TJ; Andrews P et al. Oxygenating mouthgard alleviates hypoxia during gastroscopy. Gast Endoscopy, 1992; 38(4):415-7
    18. Borody TJ; Brandl S; Andrews P. Adverse Effects of Triple Therapy, 17th International Congress of Chemotherapy (Proceedings), Berlin Futuramed-Ver-Ges Munchen 1991 Abstract
    19. Borody TJ; Brandl S; Andrews P et al. Use of 5-amino salicylic acid in irritable bowel syndrome, Gastroenterol, 1991; 102: A428
    20. Borody TJ; George LL; Brandl S et al. Helicobacter pylori-Negative Duodenal Ulcer. Am J Gastroenterol, 1991; 86(9):1154-7
    1. Borody TJ; Andrews P; Brandl S et al. Endoscopic diagnosis of Helicobacter pylori (HP) – Approaching the “gold standard”. Abstracts II, World Congresses of Gastroenterology, Sydney, Australia, 1990; PD91
    2. Rodionoff P; Hyland L; Ostapowicz N et al. Triple Therapy for Helicobacter pylori (HP) eradication –2 or 4 weeks? Abstracts I, World Congresses of Gastroenterology, Sydney, Australia, 1990; PP938
    3. Andrews P; Ostapowicz N; Lenne J et al. Who needs maintenance H2RA’s after duodenal ulcer ‘cure’? Abstracts II, World Congress of Gastroenterology, Sydney, Australia, 1990; PD332
    4. Borody TJ; Lenne J; Moore-Jones D et al. Is doxycycline more effective than tetracycline HCL in triple therapy of Helicobacter pylori? Gastroenterol, 1990 98: A24
    5. Borody TJ; Byrnes D; George L; Andrews P. How common are duodenal ulcers negative for Helicobacter pylori? Gastroenterol, 1990; 98: A23
    6. George L; Borody TJ; Andrews, P et al. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust, 1990; 153(3):145-9
    7. Borody TJ; Cole P; Noonan S et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust, 1989; 151(8):431-5
    8. Borody TJ; Noonan S; Cole P et al. L Triple Therapy for C. pylori can reverse hypochlorhydria, Gastroenterol, 1989; 96:A53
    9. Borody TJ; George L; Taylor R et al. S C. pylori-related non-ulcer dyspepsia improves after C. pylori eradication. Gastroenterol, 1989; 96:A170
    10. Borody TJ; Noonan S; Cole P et al. Duodenal ulcer recurrence in patients remaining C. pylori (CP))-negative long term post-eradication. Gastroenterol, 1989; 96:A52
    11. Borody TJ; Noonan S; Cole P et al., Oral vancomycin can reverse idiopathic constipation, Gastroenterol, 1989; 96:A52
    12. Borody TJ; George, L; Andrews, P et al. Bowel flora alteration: A potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust, 1989; 150:604 (letter)
    13. Borody TJ; Carrick, J Long term Campylobacter pylori recurrence following apparent eradication. Gastroduodenal pathology and Campylobacter pylori, 1989; 591
    14. Carrick, J; Daskalopoulos, G; Hazell, S; Lee, A; Borody, TJ. The role of Campylobacter pylori and gastric metaplasia in duodenal ulceration. Aust NZ J Med, 1988; 18:191
    15. Mitchell, HM; Lee, A; Berkowicz, J and Borody, TJ. The use of serology to diagnose active Campylobacter pylori infection, Med J Aust, 1988; 149(11-12):604-9
    16. Borody TJ; Cole P and Noonan, S. Long term Campylobacter pylori recurrence post- eradication, Gastroenterol, 1988; 94: A43
    17. Borody TJ. Double blind study of Ballobes intragastric balloon without diet or behaviour modification, International Ballobes symposium, Stockholm 1988
    18. Borody TJ. Complications and side effects of Ballobes intrgastric balloon in 427 patients, International Ballobes Symposium Stockholm 1988
    19. Borody TJ. Campylobacter, Gastritis and Ulceration, Viewpoint in Ulcer Disease. Adis Press 1987
    20. Borody TJ; Doust, B and Carrick, J; Gallstones: Optimal Diagnostic Techniques, Patient Management, 1987; 81-89
    1. Borody, TJ. Campylobacter pyloridis in the gastrointestinal tract: Recent research and implications, Current Therapeutics, 1987; 25-31
    2. Borody TJ; Carrick J; Brandl S and Cole P. Side-effects and complications in 110 consecutive patients with Danish (Ballobes) gastric balloon, Aust NZ J Med, 1987; 17(Supp 1):508
    3. Borody TJ; Carrick J; Brandl, S and Cole P. Evaluation of the Danish Gastric Balloon in the treatment of obesity. Aust NZ J Med, 1987; 17(Suppl 1):508
    4. Borody TJ; Hennessy W; Daskalopoulos G et al. Double blind trial of De-nol in non-ulcer dyspepsia associated with Campylobacter pyloridis gastritis, Gastroenterol, 1987; 92(5):1324
    5. Daskalopoulos G; Carrick J; Borody TJ et al. Do Campylobacter pyloridis and gastric metaplasia have a role in duodenal ulceration? Gastroenterol, 1987; 92(5);1363
    6. Borody TJ; Daskalopoulos G; Brandl S et al. Dyspeptic symptoms improve following eradication of gastric Campylobacter pyloridis. Gastroenterol, 1987; (5) 1324
    7. Daskalopoulos G; Borody TJ; Carrick J et al. Relationship of patients’ country of origin to endoscopic frequency of Campylobacter pyloridis gastritis. Gastroenterol, 1987; 92(5)1363
    8. Borody TJ; Carrick, J and Cole, P; Pneumogastroplasty in the obese using the Danish (Ballobes) gastric balloon, Gastroenterol, 1987; 92(5):1363
    9. Borody TJ; Carrick J; Hazell SL; Symptoms improve following the eradication of gastric Campylobacter pyloridis, Med J Aust, 1987; 146(8):450-1
    10. Carrick J; Doust B; Coleman M et al. Methyl tertiary butyl ether cholelitholysis of calculi in the gallbladder and bile ducts, Aust NZ J Med, 1987; 17(4):435-440
    11. Hazell SL; Hennessy WB; Borody TJ et al. Campylobacter pyloridis gastritis II : Distribution of bacteria and associated inflammation in the gastroduodenal environment, Am J Gastroenterol, 1987; 82:297-301
    12. Hazell SL; Borody TJ; Gal A and Lee A. Campylobacter pyloridis gastritis I: Detection of urease as a marker of bacterial colonization and gastritis, Am J Gastroenterol, 1987; 82(4):292-6
    13. Carrick J and Hennessy W. The incidence of C. pyloridis gastritis in healthy volunteers. Aust NZ J Med, 1987; 17(Suppl l):137
    14. Borody TJ; Brandl S; Carrick J and Hennessy W. Initial experience with pseumogastroplasty in obese patients. Aust NZ J Med, 1987; 17(Suppl 1):136
    15. Kellow JE; Borody TJ; Phillips SF et al. Sulfapyridine appearance in plasma and salicylazosulfapyridine. Another simple measure of intestinal transit, Gastroenterol, 1986; 91(2):396-400
    16. Hazell SL; Borody TJ; Gal A and Lee A; Rapid detection of Campylobacter pyloridis on the gastric mucosa and its association with gastritis. Aust NZ J Med, 1986; 16:608
    17. Carrick J; Doust B; Hugh T et al. Initial experience with methyl tertiary butyl ether cholelitholysis. Aust NZ J Med, 1986; 16:614
    18. Lee A; Carrick J and Borody, TJ. Campylobacter pyloridis infection as possible complication of weight loss therapy, Lancet, 1986; 2(8519):1343
    19. Borody TJ and Carrick J. Gallstones – What can be done and when to recommend it, Current Therapeutics 1986; 49-58
    20. Carrick J; Hazell S; Borody TJ and Hennessy W. Incidence of Campylobacter pyloridis gastritis in AIDS and other immunosuppressed patients, Am J Gastroenterol; 1986; 81: 853
    1. Kellow JE; Borody TJ; Phillips SF et al. Human interdigestive motility: Variations in patterns from oesophagus to colon. Gastroenterol; 1986; 91(2):386-95
    2. Borody TJ. Is gallstone dissolution practical? Aust NZ J Med, 1986; 16:118
    3. Thistle JL; Borody TJ; Quigley EMM; Tucker RL et al. Dissolution of cholesterol gallstones in the gallbladder and bile ducts in humans using methyl tertiary butyl ether, Klin Wochenschr, 1985; 63:55
    4. Borody TJ; Quigley EM; Phillips SF et al. Effects of morphine and atropine on motility and transit in the human ileum, Gastroenterol, 1985; 89(3):562-70
    5. Kellow J; Borody TJ; Brown M et al. Validation of sulfapyridine appearance in blood as a measure of small bowel transit. Gastroenterol, 1985; 88:1442
    6. Kellow J; Borody TJ; Brown M and Phillips S, Effects of morphine on motility and transit in human small intestine, Gastroenterol, 1985; 88:1442
    7. Borody TJ; Kellow J; Haddad A and Phillips S. The migrating motor complex; distribution along the human bowel, Gastroenterol 1985; 88:1331
    8. Borody TJ; Quigley EMM; Wienbeck M and Phillips SF. Effects of morphine, atropine and naloxone on the human ileocaecal sphincter, Aust NZ J Med, 1985; 15(Suppl 1):175
    9. Allen MJ; Borody TJ; Bugliosi TF et al. Rapid dissolution of gallstones by methyl tert-butyl ether, New Engl J Med, 1985; 312(4):217-220
    10. Allen MJ; Borody TJ; and Thistle JL. In-vitro dissolution of cholesterol gallstones. A study of factors influencing rate and a comparison of solvents, Gastroenterol, 1985; 89(5):1097-103
    11. Stryker SJ; Borody TJ; Phillips SF et al. Motility of the small intestine after proctocolectomy and ileal pouch-anal anastomosis, Ann Surg, 1985; 201(3):351-6
    12. Allen MJ; Borody TJ; Bugliosi TF et al. Cholelitholysis using methyl tertiary butyl ether, Gastroenterol, 1985; 88(1 pt 1):122-5
    13. Wienbeck M; Phillips SF; Quigley EMM; Borody TJ and Tucker RL. Motilitat am ileokolisohen ubergang des Menschen, Verh Dtsch Gas Inn. Med, 1984; 90:543-4
    14. Wienbeck M; Phillips SF; Borody TJ et al. Antidiarrhoeische mechanism in ileum, opiat und anticholinergika – wirkungen. Verh dtsch Gas Inn. Med, 1984; 90:543-4
    15. Quigley EMM; Borody TJ; Wienbeck M and Phillips SF. Effects of morphine on intestinal motility and transit – Studies in distal ileum and ileocolonic junction of a healthy man, Irish Soc of Gastroenterol 1984;
    16. Stryker SJ; Borody TJ; Kelly KA and Phillips SF. Small intestinal motor patterns from Ileoanal anastomosis. Digest Dis Sci, 1984; 29:548
    17. Quigley EM; Borody TJ; Phillips SF et al. Motility of the terminal ileum and ileocecal canal sphincter in healthy humans, Gastroenterol, 1984; 87(4):857-66
    18. Bugliosi TF; Allen MJ; Borody TJ et al. Rapid gallstone dissolution in dogs using MTBE and the aspiration-infusion pump, Gastroenterol, 1984; 86:1350
    19. Borody TJ; Byrnes DJ and Henderson L. Molecular forms of CCK in human postprandial plasma. Gastroenterol, 1984; 86:1032
    20. Borody TJ; Quigley EEM; Wienbeck M et al. Migrating motor complexes fade out in the human terminal ileum, Clin Res, 1984; 32:34A
    1. Borody TJ; Byrnes D; Bell D and Henderson L; The migrating motor complex – its relation to circulating CCK, motilin and pancreatic polypeptide in irritable bowel patients and in controls, Clin Res, 1984; 32:23A
    2. Borody TJ; Byrnes DJ; Titchen DA. Motilin and migrating myoeletric complexes in the pig and t he dog, Quart J Exp Physiol, 1984; 69:875-90
    3. Allen MJ; Borody TJ; La Russo NF and Thistle JL. Gallstone dissolution a comparison of solvents for direct biliary perfusion, Hepatology, 1983; 3:809
    4. Allen MJ; May GR; Borody TJ et al. Methyl tertiary butyl either rapidly dissolves gallstones in vitro and in vivo, Hepatology 1983; 3:809
    5. Borody TJ; Daskalopoulos G; Best SP et al. Cholecystokinin secretion and gallbladder contraction in patients with celiac sprue, Clin Res, 1983; 31(5):A836
    6. Quigley EMM; Borody TJ; Wienbeck M et al. Motility of the ileocolonic region in healthy man, Gut. 1983; 24:A1011
    7. Borody TJ; Byrnes D; Kamath K and Cook I. Atropine suppression test for pancreatic polypeptide-secreting tumours. Digest Dis Sci, 1983; 28:927
    8. Borody TJ; Byrnes D and Henderson L; Small intestinal motility and hormones in the irritable bowel syndrome, Aust NZ Med, 1983; 13:330
    9. Boyle M; Byrnes D; Borody TJ et al. Release of CCK by bombesin and GRP, Aust NZ J Med, 1983; 13:315
    10. Borody TJ; Byrnes D; Boyle M and Best S. Is circulating cholecystokinin a physiological stimulus for pancreatic polypeptide release in man? Digest Dis Sci, 1983; 28:927
    11. Wiley J; Borody TJ; Byrnes D et al. Cholecystokinin release by magnesium sulphate, Aust NZ J Med, 1983; 13:330
    12. Byrnes D; Borody TJ; Best S and Henderson L. Release of cholecystokinin. Aust Gastro Soc Proc, Melbourne 1982;
    13. Frommer D; Borody TJ; Maskell A and Mitchell K. Compliance, diagnostic results and costs of a large bowel screening programme, Aust Gastro Soc Proc, Canberra 1982
    14. Borody TJ; Daskalopoulos G; Best SP et al. Cholecystokinin secretion and gallbladder function in patients with coeliac disease. Aust Gastro Soc Proc Canberra 1982
    15. Byrnes D; Borody TJ; Daskalopoulos G et al. Cholecystokinin and gallbladder contraction: effect of CCK infusion, Peptides 2, 1982; (Suppl 2):259-262
    16. Borody TJ; Byrnes D and Henderson L. Relation of plasma CCK and motilin to gallbladder contraction in man. Aust NZ J Med, 1982; 12:115
    17. Borody TJ and Byrnes D. Plasma cholecystokin, motilin and pancreatic polypeptide and the migrating motor myoelectric complex in man, Aust NZ J Med, 1982; 12:100
    18. Byrnes DJ, Henderson L, Borody TJ and Rehfeld JF. Radioimmunoassay of cholecystokinin in human plasma. Clinica Chimica Acta, 111 (1981) 81-89
    19. Borody TJ; Byrnes D and Tichen D. Migrating myoelectric complexes and motilin in the dog, J Physiol, 1981; 320:61-62
    20. Daskalopoulos G; Borody TJ; Grant I et al. Cholecystokinin and gallbladder emptying in normal subjects and patients with gallstones. Proceedings of the Brain/Gut Conference, 1981; Page 45
    1. Boyle M; Byrnes D; Borody TJ and Henderson L. Effects of food ingestion on plasma bombesin, Proceedings of the Brain/Gut Conference. Florence, 1981; page 28
    2. Borody TJ; Byrnes D and Henderson L. Plasma Cholecystokinin and the migrating myoelectric complex in man, Proceedings of the Brain/Gut Conference, Florence, 1981; P27
    3. Gude RA; Stokes J; Borody TJ. Myasthenia gravis in Melanesians in the Solomon Islands. PNG Med J, 1981; 24(1):50-3
    4. Borody TJ; Byrnes D; Slowiaczek J and Titchen D Effect of motilin antiserum on porcine IDMCS. Reg Peptides, 1981; (suppl):S13
    5. Borody TJ; Byrnes D; Slowiaczek J and Titchen D. Immunoneutralisation of motilin. T. Horm Metabol Res, 1981; 13(8):470-1
    6. Borody TJ; Byrnes D; Slowiaczek J and Titchen D. Motilin and migrating myoelectric complexes in pigs, J Physiol, 1981; 310; 37-8
    7. Byrnes,DJ; Henderson L; Borody TJ and Rehfeld JF. Radioimmunoassay of cholecystokinin in human plasma, Clin Chem Acta, Volume III, 1981; (1):81-9
    8. Byrnes, D; Borody, TJ and Henderson, L; Plasma cholecystokin Reg Peptides I, (Suppl):S15
    9. Byrnes, D; Henderson, L; Borody TJ; Rehfeld JH. Radioimmunoassay of cholecystokinin. AustNZ J Med, 1980; 10:365
    10. Borody TJ; Byrnes D; Henderson L. Effect of renal function and age on plasma motilin andpancreatic polypeptide, Aust NZ J Med, 1980; 10:365
    11. Borody TJ; Byrnes,D and Henderson L. In-vitro release of motilin for human duodenal mucosa,Aust NZ J Med, 1980; 10:365
    12. Borody TJ; Byrnes D and Henderson L. Mechanisms of motilin release by metoclopramide,Reg Peptides I, 1980; (Suppl 1):S13
    13. Byrnes, D; Henderson L; Meredith C and Borody TJ. Release of motilin by metoclopramide, AustNZ J Med, 1980; 10:109
    14. Borody TJ; Byrnes D; Slowiaczek J; Titchen D. Effect of Motilin antiserum infusion on PorcineIDMCS, Reg. Peptides; 1980;1(S1):S13
    15. Borody TJ; Chinwah PM; Graham GG et al. Chlorbutol toxicity and dependence, Med J Aust1979; 1(7):288
    16. Borody TJ; Dickson MR; Wilhelm DL. Inflammatory response in chemical injury in liver, ProceSoc Aust Exp pathologists 1971 Canberra

    BOOK CHAPTERS:

    1. Borody TJ, Campbell J. (2012) Gut Microbiota-Brain Connection. Arranga T, Viadro CI, Underwood L (eds) in: Bugs, Bowel & Behaviour: The Ground-Breaking Story of the Gut-Brain Connection. Arranga T (ed) New York USA, Skyhorse Publishing
    2. Borody TJ, Campbell J. (2012) Fecal Microbiota Transplantation: Techniques, Applications and Issues. In Gerald Freidman (Ed) Gastroenterology Clinics of North America Clinical Applications of Probiotics in Gastroenterology: Questions and Answers, (pp. 781-803) Philadelphia USA, Elsevier
    1. Borody TJ; Leis S; Pang G; Wettstein AR, (2006) Fecal bacteriotherapy in the treatment of recurrent C. difficile infection.. In: Up-to-date, Rose, BD (Ed), Up-to-date, Waltham
    2. Borody TJ; Conway PL; Koch TR. Probiotics and the Colon: Therapeutic and Prophylactic Uses. (ed) In: Colonic Diseases. Humana Press; 2003; 141-161
    3. Borody TJ; Clancy R; Warren EF et al. Antibiotic sensitivities of Helicobacter pylori vary at different gastric mucosal sites. RH Hunt, GNJ Tytgat (eds) In; Helicobacter pylori: Basic Mechanisms to Clinical Cure Maui 2002; pg 373-82
    4. Borody, TJ; Pang G; Clancy R; Ren Z. IgG2 Anti-H. pylori antibody assay for the diagnosis of ‘high cancer risk’ H. pylori infection. RH Hunt, GNJ Tytgat (eds) In: Helicobacter pylori: Basic Mechanisms to Clinical Cure Maui, 2002
    5. Clancy R; Borody TJ; Ren Z; Pang G. Can the response to eradication therapy in helicobacter pylori infection be predicted? RH Hunt, GNJ Tytgat (eds), In: Helicobacter pylori: Basic Mechanisms to Clinical Cure, 2002
    6. Borody TJ; Clancy R; Ren Z et al. Eradication failure – the view from within. In: Proceedings and abstracts of the 4th Western Pacific Helicobacter pylori Congress, Perth, Australia. 2002
    7. Borody TJ. Quadruple should be first-line therapy for Helicobacter pylori infection. Hunt RH, Tytgat GNJ (eds) In: Helicobacter pylori-Basic Mechanisms to Clinical Cure 2000; Chapter 67:623-629
    8. Clancy R; Borody TJ. What role for clarithromycin in the treatment of Helicobacter pylori infection? Hunt RH, Tytgat GNJ (eds) In: Helicobacter pylori – Basic Mechanisms to Clinical Cure 2000; Chapter 63: 587-591
    9. Borody TJ. Consultant Editor for the AMA’s Home Medical Guide to your bowels. 2000
    10. Borody TJ; Shortis,NP. Treatment of Patients with failed eradication – a personal view. Hunt RH, Tytgat GNJ (eds) In: Helicobacter pylori – Basic Mechanisms to Clinical Cure 1996; Chapter 36; 357-365
    11. Borody TJ; Shortis NP; Chongnan J et al. Practical, Optimal Quad H. pylori Eradication Program for First-Line & Eradication Failure (EF) Patients. RH Hunt, GNJ Tytgat (eds) In: Helicobacter pylori: Basic Mechanisms to Clinical Cure, Ottawa 1996
    12. Borody, TJ; Diarrhoea – Acute and Chronic. Speight TM (eds) In: MIMS Disease Index, Singapore, Kyodo Printing Co P/L, 1992
    13. Borody TJ; Brandl, S; Andrews, P. Adverse effects of Triple Therapy. Recent Advances in Chemotherapy: proceedings of the 17th International Congress of Chemotherapy, Ed by I D Adamas, H Lode and E Rubenstein In: Futuramed-Verl Berlin, Munich, 1991; 632-633
    14. Borody TJ and Carrick J. Long term Campylobacter pylori recurrence following apparent eradication. Bio-Medical Division F Megraud & H Lamouliatte, Editors. Elsevier Science Publishers, 1991
    15. Carrick J; Daskalopoulos G; Borody TJ. Ethnic differences in the prevalence of Campylobacter pyloridis infection. Peterson WL (ed) In: Campylobacter pylori: a Multi-Disciplinary Workshop, Colorado USA , July, 1987

    BOOKS

    1. Borody, T; Peek, R and Rosendahl, C. Handbook of Obstetrics and Gynaecology. Dai Nippon Press, Hong Kong 1975

It just takes courage and takes, years and years of perseverance to change paradigms.

See all Professor Borody’s research papers and awards here ORCID ID

ABC news report about Professor Borody

For conference organisers & media